rhCollagen (Recombinant human collagen)
This document is technical information about materials. It does not recommend any procedure or product.
In brief
Collagen produced by expressing human collagen gene sequences in a host organism rather than extracting protein from animal tissue. The literature presents the source as the point of the material: it removes the animal-tissue disease and immunogenicity questions that attach to extracted collagen, and it allows a defined type to be produced.
Regulatory identity by market
COS cosmetic · MD medical device · RX drug · — not established in public sources
Identity & physical properties
| Synonyms | Recombinant human collagen, rhCollagen, Recombinant humanized collagen, rhCol |
|---|---|
| Family | ECM structural protein — recombinant |
| Morphology | Supplied in several forms depending on application, including solutions, microgels and dressings |
| Molecular weight | Depends on the construct. Many recombinant products are fragments rather than full-length triple-helical collagen, and the literature does not always state which |
Mechanism
This material supplies extracellular matrix protein rather than provoking the host to make it. Reported work describes recombinant type III collagen applied to ultraviolet-damaged skin in an animal model, and an injectable type III microgel developed as a dermal filler.
Evidence
| PMID | Study type | Summary |
|---|---|---|
| 34938920 | in vivo | Recombinant humanized type III collagen assessed on ultraviolet-photoaged skin in an animal model |
| 40852182 | in vivo | Recombinant human collagen type III microgel developed as an injectable dermal filler for aging skin |
| 31261996 | review | Review of collagen sources for skin wound-healing biomaterials, covering types I, III and VII |
| 40720447 | review | Review of collagen-based products across wound care, skin care and consumer markets |
Regulatory identity — detail
| Market | Classification | Note | Basis |
|---|---|---|---|
| KR | unclassified | Not established from public sources as of the revision date below. Classification is likely to depend on the presentation and the claim rather than on the protein itself. | — |
| EU | unclassified | Not established from public sources as of the revision date below. | — |
| US | unclassified | As of the revision date below, the full set of FDA premarket approval records listed under the generic name 'implant, dermal, for aesthetic use' was reviewed (22 distinct approvals), and a recombinant human collagen dermal implant was not found in that list. Listing through a route outside this generic name cannot be ruled out, so this is left unestablished. | — |
| JP | unclassified | Not established from public sources as of the revision date below. | — |
| CN | unclassified | Not established from public sources as of the revision date below. | — |
| VN | unclassified | Not established from public sources as of the revision date below. | — |
Limitations & open questions
The term covers a wide range of constructs. Many products described as recombinant human collagen are fragments or single domains rather than full-length triple-helical protein, and a claim about one construct does not describe the category. The aesthetic evidence cited here is preclinical: an animal photoaging model and a filler development study. No randomised clinical trial in a facial aesthetic indication was identified for this page as of the revision date below.
All statements on this page are drawn from the cited literature. Where a market’s regulatory classification could not be established from public sources, it is marked as not established rather than inferred.
The source is the argument
Extracted collagen carries questions that follow from its origin in animal tissue. Recombinant production is presented in the literature as the answer to those questions rather than as a change in what collagen does once it is in the skin. Reading the two side by side is therefore mostly a question about manufacturing and risk profile, not about a different biological effect.
Check the construct before accepting a claim
“Recombinant human collagen” names a production route, not a molecule. Whether a given product is a full-length triple helix or a fragment changes what it can be expected to do structurally, and product literature does not always say. This is the first thing to establish when a claim is presented.